Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

March 27, 2015

Primary Completion Date

September 1, 2017

Study Completion Date

March 2, 2023

Conditions
Colon AdenocarcinomaRectal AdenocarcinomaStage III Colorectal Cancer AJCC v7Stage IIIA Colorectal Cancer AJCC v7Stage IIIB Colorectal Cancer AJCC v7Stage IIIC Colorectal Cancer AJCC v7Stage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7
Interventions
DRUG

Clobetasol Propionate

Given topically

OTHER

Pharmacological Study

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Regorafenib

Given PO

Trial Locations (22)

13057

Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse

14263

Roswell Park Cancer Institute, Buffalo

17822

Geisinger Medical Center, Danville

27157

Wake Forest University Health Sciences, Winston-Salem

37660

Wellmont Medical Associates Oncology and Hematology-Kingsport, Kingsport

43210

Ohio State University Comprehensive Cancer Center, Columbus

43623

Toledo Clinic Cancer Centers-Toledo, Toledo

46628

Northern Indiana Cancer Research Consortium, South Bend

51101

Siouxland Regional Cancer Center, Sioux City

54301

Saint Vincent Hospital Cancer Center Green Bay, Green Bay

54449

Marshfield Clinic, Marshfield

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

55905

Mayo Clinic, Rochester

61615

Illinois CancerCare-Peoria, Peoria

63110

Washington University School of Medicine, St Louis

68106

Missouri Valley Cancer Consortium, Omaha

68198

University of Nebraska Medical Center, Omaha

85054

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

98195

University of Washington Medical Center, Seattle

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER

NCT02368886 - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter